We are live on ! Find out more
HAE icon

Haemonetics

300 hedge funds and large institutions have $4.19B invested in Haemonetics in 2023 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 110 increasing their positions, 113 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $8.61M | Put options by funds: $5.34M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

19% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 36

2% more funds holding

Funds holding: 293 → 300 (+7)

0.32% more ownership

Funds ownership: 99.53% → 99.85% (+0.32%)

3% less repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 113

3% less capital inflows, than outflows

Capital inflows: $288M | Capital outflows: $297M

Holders
300
Holders Change
+7
Holders Change %
+2.39%
% of All Funds
4.77%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
43
Increased
110
Reduced
113
Closed
36
Calls
$8.61​M
Puts
$5.34​M
Net Calls
+$3.27​M
Net Calls Change
+$7.59​M

HAE Hedge Fund Activity: Q1 2023 in Review

300 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2023, worth a combined $4.19B — up 5.7% from $3.96B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new HAE positions and 36 closed out — a net gain of 7 holders — while 110 added to existing stakes and 113 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $56.5M. The largest seller was Wellington Management Group, cutting an estimated $36.9M.

  • 300 institutional investors held Haemonetics (HAE) as of Q1 2023, up from 293 in Q4 2022.
  • Funds reported $4.19B of Haemonetics stock for Q1 2023, up 5.7% quarter-over-quarter.
  • 43 funds opened new Haemonetics positions in Q1 2023 and 36 closed out, a net change of +7 holders.
  • The largest Haemonetics buyer in Q1 2023 was Capital Research Global Investors, an estimated $56.5M added.
  • The largest Haemonetics seller in Q1 2023 was Wellington Management Group, an estimated $36.9M sold.

Based on aggregated 13F filings for Q1 2023.